Progen Pharmaceuticals Patent granted in important Japanese market
Brisbane, Australia, 28th June 2010. The Directors of Progen Pharmaceuticals Limited (ASX:PGL,
NASDAQ:PGLA) today announced the granting of a Japanese patent for the Preparation and Use of Sulfated
Oligosaccharides which includes muparfostat (PI-88).
Progen Pharmaceuticals Limited has an exclusive worldwide license to muparfostat (PI-88) technology from the
Australian National University.
“Japan is an important market for liver cancer and the granting of this patent provides additional coverage in this
key territory,” said Sue MacLeman, Chief Executive Officer, Progen Pharmaceuticals Ltd.
PI-88 is one of a class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a
first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumour activity is based on inhibition of two
biological processes — angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to
other sites) — critical to the growth and progression of cancer.
The patent number is 4514240. The applicant for the patent is the Australian National University. The date of
grant was 21 May 2010 and the patent term is 20 years from April 24 1996 (date of commencement of
patent term), expiring 24
Historically, PI-88 was the result of fully funded research collaboration with Professor Chris Parish’s group at the
John Curtin School of Medical Research at The Australian National University.
About Progen Pharmaceuticals Ltd
Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and
commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a
focus and strength in anti-cancer drug discovery and development. Progen has operations in Australia and the
United States of America. www.progen-pharma.com
ABN 82 010 975 612